Kamada Reiterates 2025 Revenue Guidance of $178M to $182M
"This award extension, together with continued supply of KAMRAB, our anti-Rabies Immunoglobulin product used in Canada, and GLASSIA, our AAT product licensed to Takeda for distribution in Canada, validates our position as the leading supplier of specialty plasma derived products in Canada," said Amir London, Kamada's CEO. "We remain confident that significant commercial potential exists for our AAT and specialty immunoglobulin portfolio in the international markets and intend to continue pursuing additional contracts in key strategic territories." As recently stated, based on our strong, consistent performance during 2025, we have reiterated our full-year 2025 revenue guidance of between $178M to $182M and our annual adjusted EBITDA guidance of $40M to $44M. Additionally, we project double-digit growth in revenues and profitability in 2026 through our robust commercial portfolio, growing biosimilar portfolio in Israel, and the expansion of normal source plasma sales. In parallel, we continue to focus on pursuing new commercial stage business development opportunities, leveraging our strong cash position, to support continued long-term growth," concluded Mr. London.
Get Free Real-Time Notifications for Any Stock
Analyst Views on KMDA
About KMDA
About the author
Analyst Predicts Increase in Hubspot Stock, Along with Insights on McGraw Hill, UHS, and Other Stocks.
Report Overview: Recent reports from investment and research firms provide insights into analysts' perspectives on various companies.
Disclaimer: The views expressed in these reports do not reflect the opinions or recommendations of Barron’s.
Investment Services: Some report issuers may have existing or potential investment-banking relationships with the companies analyzed.
Purpose of Reports: The reports serve as a sampling of analyst thinking rather than definitive investment advice.
Kamada Forecasts $200M-$205M Revenue for 2026 with 13% Growth
- 2026 Financial Outlook: Kamada projects revenues of $200 million to $205 million for 2026, representing a 13% year-over-year increase based on the midpoint of 2025 guidance, highlighting the company's ongoing organic growth potential across its diverse product portfolio in the biopharmaceutical sector.
- Adjusted EBITDA Growth: The company anticipates adjusted EBITDA to reach $50 million to $53 million in 2026, reflecting a 23% increase from the midpoint of 2025, which signifies a substantial enhancement in profitability and boosts investor confidence.
- Strong Cash Position: Kamada expects to end 2025 with approximately $75 million in cash, ensuring financial flexibility for future investments and business expansions, thereby strengthening its competitive edge in global markets.
- Strategic Development Focus: The company will continue to prioritize new business development and M&A transactions to accelerate long-term profitable growth, a strategy that will enrich its marketed product portfolio and generate synergies with existing operations.
